adalimumab-adaz (Hyrimoz) vs adalimumab-adbm (Cyltezo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

adalimumab-adaz (Hyrimoz)

Marketed by Sandoz Group AG and partners

Approved in Crohn's Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT02871635 · Phase 3 · completed

This was a randomized, double-blind trial against the reference adalimumab product, with a validated Crohn's disease activity score as the primary endpoint. Clinical response at week 4 was similar in both groups (risk ratio 0.945, 90% CI 0.870 to 1.028), within the prespecified non-inferiority margin, and 147 people were randomized against a planned 130.

Hanauer et al. (Lancet Gastroenterol Hepatol, 2021; PMID 34388360) report different figures for this outcome, clinical response in 61 of 68 patients (90%) with BI 695501 and 68 of 72 (94%) with the reference product, because the registry figures are model-based least-squares means.

Reported efficacy

Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline) at Week 4: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol). (met)

Result source: NCT02871635

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adaz (Hyrimoz)adalimumab-adbm (Cyltezo)
Clinical remission (induction)—Not reported—Not reported
Endoscopic response (induction)—Not reported—Not reported
Clinical remission (maintenance)—Not reported68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT02871635
Endoscopic response (maintenance)—Not reported—Not reported

Clinical remission (induction)

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported

Endoscopic response (induction)

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported

Clinical remission (maintenance)

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT02871635

Endoscopic response (maintenance)

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adaz (Hyrimoz): no structured comparison results are available for Crohn's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adaz (Hyrimoz): 0 of 4 rows · adalimumab-adbm (Cyltezo): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-adbm (Cyltezo)
Dropout rate
25%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Discontinued due to AEs
5.6%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Serious AEs
—BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
8.3%BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
2.8%BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Most frequent reported AEs
arthralgia 8.3%
respiratory tract infection 6.9%
crohn's disease 5.6%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
nasopharyngitis 6.9%
weight increased 4.2%
arthralgia 2.8%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-adbm (Cyltezo)

CDAI ≥ 70 88% (n=68) vs 93.1% (n=72) Humira EU @ 4wk
responder rate · % of participants
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
87.4% (n=68) vs 87.4% (n=72) Humira EU @ 24wk
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Clinical Remission 68.6% (n=68) vs 76.2% (n=72) Humira EU @ 24wk
responder rate · % of participants
NCT02871635 · Phase 3 · Crohn's Disease · phase 3

Psoriasis

Shared mechanism: TNF-alpha · full Psoriasis pipeline

adalimumab-adaz (Hyrimoz)

Marketed by Sandoz Group AG and partners

Approved in Psoriasismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Psoriasismonoclonal antibody
Weak signal

NCT03210259 · Phase 3 · completed

After a 14-week Humira run-in, 238 patients were randomized to switch between Cyltezo and Humira or continue Humira in a double-blind active-controlled period. Both primary pharmacokinetic comparisons met the prespecified equivalence range, but these were drug-level measures rather than direct clinical psoriasis outcomes, so the evidence is moderate. Its registered primary outcomes are pharmacokinetic measures with no comparison, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adaz (Hyrimoz)adalimumab-adbm (Cyltezo)
PASI 75—Not reported—Not reported
PASI 90—Not reported—Not reported
PASI 100—Not reported—Not reported
sPGA 0/1—Not reported—Not reported
DLQI, change—Not reported—Not reported

PASI 75

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported

PASI 90

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported

PASI 100

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported

sPGA 0/1

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported

DLQI, change

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adaz (Hyrimoz): registry results are on file for Psoriasis, but their comparison mappings are not yet available.

adalimumab-adbm (Cyltezo): registry results are on file for Psoriasis, but their comparison mappings are not yet available.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-adaz (Hyrimoz)

Marketed by Sandoz Group AG and partners

Approved in Rheumatoid Arthritismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02137226 · Phase 3 · completed

The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.

No aligned efficacy figure on record for this race.

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adaz (Hyrimoz)adalimumab-adbm (Cyltezo)
ACR20—Not reported—Not reported
ACR50—Not reported—Not reported
ACR70—Not reported—Not reported
DAS28-CRP remission—Not reported—Not reported
HAQ-DI, change—Not reported—Not reported
Modified Sharp score, change—Not reported—Not reported

ACR20

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported

ACR50

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported

ACR70

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported

DAS28-CRP remission

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported

HAQ-DI, change

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported

Modified Sharp score, change

adalimumab-adaz (Hyrimoz)
—Not reported
adalimumab-adbm (Cyltezo)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adaz (Hyrimoz): no structured comparison results are available for Rheumatoid Arthritis.

adalimumab-adbm (Cyltezo): registry results are on file for Rheumatoid Arthritis, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adaz (Hyrimoz)'s landscape · adalimumab-adbm (Cyltezo)'s landscape